Search

Your search keyword '"Modiano, Jaime F."' showing total 644 results
Start Over Author "Modiano, Jaime F."
644 results on '"Modiano, Jaime F."'

1. Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma

Author

Makielski, Kelly M., Sarver, Aaron L., Henson, Michael S., Stuebner, Kathleen M., Borgatti, Antonella, Suksanpaisan, Lukkana, Preusser, Caitlin, Tabaran, Alexandru-Flaviu, Cornax, Ingrid, O’Sullivan, M. Gerard, Chehadeh, Andrea, Groschen, Donna, Bergsrud, Kelly, Pracht, Sara, Winter, Amber, Mills, Lauren J., Schwabenlander, Marc D., Wolfe, Melissa, Farrar, Michael A., Cutter, Gary R., Koopmeiners, Joseph S., Russell, Stephen J., Modiano, Jaime F., and Naik, Shruthi

Published
2023
Full Text
View/download PDF

4. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer.

Author

Judge, Sean J, Yanagisawa, Mio, Sturgill, Ian R, Bateni, Sarah B, Gingrich, Alicia A, Foltz, Jennifer A, Lee, Dean A, Modiano, Jaime F, Monjazeb, Arta M, Culp, William TN, Rebhun, Robert B, Murphy, William J, Kent, Michael S, and Canter, Robert J

Subjects
Killer Cells, Natural, Animals, Dogs, Osteosarcoma, Bone Neoplasms, Dog Diseases, Cytokines, Adoptive Transfer, Palliative Care, Follow-Up Studies, Cytotoxicity, Immunologic, Female, Male, Granzymes, Natural Cytotoxicity Triggering Receptor 1, Transcriptome, Biomarkers, Tumor, Progression-Free Survival, General Science & Technology
Abstract

We have previously reported radiation-induced sensitization of canine osteosarcoma (OSA) to natural killer (NK) therapy, including results from a first-in-dog clinical trial. Here, we report correlative analyses of blood and tissue specimens for signals of immune activation in trial subjects. Among 10 dogs treated with palliative radiotherapy (RT) and intra-tumoral adoptive NK transfer, we performed ELISA on serum cytokines, flow cytometry for immune phenotype of PBMCs, and PCR on tumor tissue for immune-related gene expression. We then queried The Cancer Genome Atlas (TCGA) to evaluate the association of cytotoxic/immune-related gene expression with human sarcoma survival. Updated survival analysis revealed five 6-month survivors, including one dog who lived 17.9 months. Using feeder line co-culture for NK expansion, we observed maximal activation of dog NK cells on day 17-19 post isolation with near 100% expression of granzyme B and NKp46 and high cytotoxic function in the injected NK product. Among dogs on trial, we observed a trend for higher baseline serum IL-6 to predict worse lung metastasis-free and overall survival (P = 0.08). PCR analysis revealed low absolute gene expression of CD3, CD8, and NKG2D in untreated OSA. Among treated dogs, there was marked heterogeneity in the expression of immune-related genes pre- and post-treatment, but increases in CD3 and CD8 gene expression were higher among dogs that lived > 6 months compared to those who did not. Analysis of the TCGA confirmed significant differences in survival among human sarcoma patients with high and low expression of genes associated with greater immune activation and cytotoxicity (CD3e, CD8a, IFN-γ, perforin, and CD122/IL-2 receptor beta). Updated results from a first-in-dog clinical trial of palliative RT and autologous NK cell immunotherapy for OSA illustrate the translational relevance of companion dogs for novel cancer therapies. Similar to human studies, analyses of immune markers from canine serum, PBMCs, and tumor tissue are feasible and provide insight into potential biomarkers of response and resistance.

Published
2020

6. FIGURE 5 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

Author

Kim, Jong Hyuk, primary, Schulte, Ashley J., primary, Sarver, Aaron L., primary, Lee, Donghee, primary, Angelos, Mathew G., primary, Frantz, Aric M., primary, Forster, Colleen L., primary, O'Brien, Timothy D., primary, Cornax, Ingrid, primary, O'Sullivan, M. Gerard, primary, Cheng, Nuojin, primary, Lewellen, Mitzi, primary, Oseth, LeAnn, primary, Kumar, Sunil, primary, Bullman, Susan, primary, Pedamallu, Chandra Sekhar, primary, Goyal, Sagar M., primary, Meyerson, Matthew, primary, Lund, Troy C., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Dickerson, Erin B., primary, Kaufman, Dan S., primary, and Modiano, Jaime F., primary

Published
2024
Full Text
View/download PDF

7. FIGURE 2 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

Author

Kim, Jong Hyuk, primary, Schulte, Ashley J., primary, Sarver, Aaron L., primary, Lee, Donghee, primary, Angelos, Mathew G., primary, Frantz, Aric M., primary, Forster, Colleen L., primary, O'Brien, Timothy D., primary, Cornax, Ingrid, primary, O'Sullivan, M. Gerard, primary, Cheng, Nuojin, primary, Lewellen, Mitzi, primary, Oseth, LeAnn, primary, Kumar, Sunil, primary, Bullman, Susan, primary, Pedamallu, Chandra Sekhar, primary, Goyal, Sagar M., primary, Meyerson, Matthew, primary, Lund, Troy C., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Dickerson, Erin B., primary, Kaufman, Dan S., primary, and Modiano, Jaime F., primary

Published
2024
Full Text
View/download PDF

8. Supplementary Figure S2 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

Author

Kim, Jong Hyuk, primary, Schulte, Ashley J., primary, Sarver, Aaron L., primary, Lee, Donghee, primary, Angelos, Mathew G., primary, Frantz, Aric M., primary, Forster, Colleen L., primary, O'Brien, Timothy D., primary, Cornax, Ingrid, primary, O'Sullivan, M. Gerard, primary, Cheng, Nuojin, primary, Lewellen, Mitzi, primary, Oseth, LeAnn, primary, Kumar, Sunil, primary, Bullman, Susan, primary, Pedamallu, Chandra Sekhar, primary, Goyal, Sagar M., primary, Meyerson, Matthew, primary, Lund, Troy C., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Dickerson, Erin B., primary, Kaufman, Dan S., primary, and Modiano, Jaime F., primary

Published
2024
Full Text
View/download PDF

9. FIGURE 3 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

Author

Kim, Jong Hyuk, primary, Schulte, Ashley J., primary, Sarver, Aaron L., primary, Lee, Donghee, primary, Angelos, Mathew G., primary, Frantz, Aric M., primary, Forster, Colleen L., primary, O'Brien, Timothy D., primary, Cornax, Ingrid, primary, O'Sullivan, M. Gerard, primary, Cheng, Nuojin, primary, Lewellen, Mitzi, primary, Oseth, LeAnn, primary, Kumar, Sunil, primary, Bullman, Susan, primary, Pedamallu, Chandra Sekhar, primary, Goyal, Sagar M., primary, Meyerson, Matthew, primary, Lund, Troy C., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Dickerson, Erin B., primary, Kaufman, Dan S., primary, and Modiano, Jaime F., primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table S5 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

Author

Kim, Jong Hyuk, primary, Schulte, Ashley J., primary, Sarver, Aaron L., primary, Lee, Donghee, primary, Angelos, Mathew G., primary, Frantz, Aric M., primary, Forster, Colleen L., primary, O'Brien, Timothy D., primary, Cornax, Ingrid, primary, O'Sullivan, M. Gerard, primary, Cheng, Nuojin, primary, Lewellen, Mitzi, primary, Oseth, LeAnn, primary, Kumar, Sunil, primary, Bullman, Susan, primary, Pedamallu, Chandra Sekhar, primary, Goyal, Sagar M., primary, Meyerson, Matthew, primary, Lund, Troy C., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Dickerson, Erin B., primary, Kaufman, Dan S., primary, and Modiano, Jaime F., primary

Published
2024
Full Text
View/download PDF

11. FIGURE 4 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

Author

Kim, Jong Hyuk, primary, Schulte, Ashley J., primary, Sarver, Aaron L., primary, Lee, Donghee, primary, Angelos, Mathew G., primary, Frantz, Aric M., primary, Forster, Colleen L., primary, O'Brien, Timothy D., primary, Cornax, Ingrid, primary, O'Sullivan, M. Gerard, primary, Cheng, Nuojin, primary, Lewellen, Mitzi, primary, Oseth, LeAnn, primary, Kumar, Sunil, primary, Bullman, Susan, primary, Pedamallu, Chandra Sekhar, primary, Goyal, Sagar M., primary, Meyerson, Matthew, primary, Lund, Troy C., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Dickerson, Erin B., primary, Kaufman, Dan S., primary, and Modiano, Jaime F., primary

Published
2024
Full Text
View/download PDF

12. FIGURE 1 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

Author

Kim, Jong Hyuk, primary, Schulte, Ashley J., primary, Sarver, Aaron L., primary, Lee, Donghee, primary, Angelos, Mathew G., primary, Frantz, Aric M., primary, Forster, Colleen L., primary, O'Brien, Timothy D., primary, Cornax, Ingrid, primary, O'Sullivan, M. Gerard, primary, Cheng, Nuojin, primary, Lewellen, Mitzi, primary, Oseth, LeAnn, primary, Kumar, Sunil, primary, Bullman, Susan, primary, Pedamallu, Chandra Sekhar, primary, Goyal, Sagar M., primary, Meyerson, Matthew, primary, Lund, Troy C., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Dickerson, Erin B., primary, Kaufman, Dan S., primary, and Modiano, Jaime F., primary

Published
2024
Full Text
View/download PDF

13. Data from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

Author

Kim, Jong Hyuk, primary, Schulte, Ashley J., primary, Sarver, Aaron L., primary, Lee, Donghee, primary, Angelos, Mathew G., primary, Frantz, Aric M., primary, Forster, Colleen L., primary, O'Brien, Timothy D., primary, Cornax, Ingrid, primary, O'Sullivan, M. Gerard, primary, Cheng, Nuojin, primary, Lewellen, Mitzi, primary, Oseth, LeAnn, primary, Kumar, Sunil, primary, Bullman, Susan, primary, Pedamallu, Chandra Sekhar, primary, Goyal, Sagar M., primary, Meyerson, Matthew, primary, Lund, Troy C., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Dickerson, Erin B., primary, Kaufman, Dan S., primary, and Modiano, Jaime F., primary

Published
2024
Full Text
View/download PDF

14. Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy.

Author

Gingrich, Alicia A, Modiano, Jaime F, and Canter, Robert J

Subjects
cancer, canine, immunotherapy, natural killer cell, translational research, Clinical Sciences
Abstract

Natural killer (NK) cells of the innate immune system are a key focus of research within the field of immuno-oncology based on their ability to recognize and eliminate malignant cells without prior sensitization or priming. However, barriers have arisen in the effective translation of NK cells to the clinic, in part because of critical species differences between mice and humans. Companion animals, especially dogs, are valuable species for overcoming many of these barriers, as dogs develop spontaneous tumors in the setting of an intact immune system, and the genetic and epigenetic factors that underlie oncogenesis appear to be similar between dogs and humans. Here, we summarize the current state of knowledge for dog NK cells, including cell surface marker phenotype, key NK genes and genetic regulation, similarities and differences of dog NK cells to other mammals, especially human and mouse, expression of canonical inhibitory and activating receptors, ex vivo expansion techniques, and current and future clinical applications. While dog NK cells are not as well described as those in humans and mice, the knowledge of the field is increasing and clinical applications in dogs can potentially advance the field of human NK biology and therapy. Better characterization is needed to truly understand the similarities and differences of dog NK cells with mouse and human. This will allow for the canine model to speed clinical translation of NK immunotherapy studies and overcome key barriers in the optimization of NK cancer immunotherapy, including trafficking, longevity, and maximal in vivo support.

Published
2019

16. Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning

Author

Makielski, Kelly M., Donnelly, Alicia J., Khammanivong, Ali, Scott, Milcah C., Ortiz, Andrea R., Galvan, Dana C., Tomiyasu, Hirotaka, Amaya, Clarissa, Ward, Kristin A., Montoya, Alexa, Garbe, John R., Mills, Lauren J., Cutter, Gary R., Fenger, Joelle M., Kisseberth, William C., O’Brien, Timothy D., Weigel, Brenda J., Spector, Logan G., Bryan, Brad A., Subramanian, Subbaya, and Modiano, Jaime F.

Published
2021
Full Text
View/download PDF

17. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.

Author

Canter, Robert J, Grossenbacher, Steven K, Foltz, Jennifer A, Sturgill, Ian R, Park, Jiwon S, Luna, Jesus I, Kent, Michael S, Culp, William TN, Chen, Mingyi, Modiano, Jaime F, Monjazeb, Arta M, Lee, Dean A, and Murphy, William J

Subjects
Killer Cells, Natural, K562 Cells, Animals, Dogs, Humans, Osteosarcoma, Sarcoma, Experimental, Dog Diseases, Combined Modality Therapy, Radiotherapy, Coculture Techniques, Xenograft Model Antitumor Assays, Cytotoxicity, Immunologic, Adoptive immunotherapy, Canine, Natural killer cells, Sarcoma
Abstract

BACKGROUND:We have previously shown that radiotherapy (RT) augments natural killer (NK) functions in pre-clinical models of human and mouse cancers, including sarcomas. Since dogs are an excellent outbred model for immunotherapy studies, we sought to assess RT plus local autologous NK transfer in canine sarcomas. METHODS:Dog NK cells (CD5dim, NKp46+) were isolated from PBMCs and expanded with irradiated K562-C9-mIL21 feeder cells and 100 IU/mL recombinant human IL-2. NK homing and cytotoxicity ± RT were evaluated using canine osteosarcoma tumor lines and dog patient-derived xenografts (PDX). In a first-in-dog clinical trial for spontaneous osteosarcoma, we evaluated RT and intra-tumoral autologous NK transfer. RESULTS:After 14 days, mean NK expansion and yield were 19.0-fold (±8.6) and 258.9(±76.1) ×106 cells, respectively. Post-RT, NK cytotoxicity increased in a dose-dependent fashion in vitro reaching ~ 80% at effector:target ratios of ≥10:1 (P

Published
2017

18. Whole Genome 3D Blood Biopsy Profiling of Canine Cancers: Development and Validation of EpiSwitch Multi-Choice Array-Based Diagnostic Test.

Author

Hunter, Ewan, primary, Salter, Matthew, additional, Powell, Ryan, additional, Dring, Ann, additional, Naithani, Tarun, additional, Vugrinec, Dominik, additional, Shliaiev, Kyrylo, additional, Issa, Mutaz, additional, Weston, Cicely, additional, Hatton, Abigail, additional, Gebregzabhar, Abel, additional, Green, Jane, additional, Blum, Anthony, additional, Guiel, Thomas, additional, Fritz, Sara, additional, Seelig, Davis, additional, Modiano, Jaime F, additional, and Akoulitchev, Alexandre, additional

Published
2024
Full Text
View/download PDF

19. Canine cancer immunotherapy studies: linking mouse and human

Author

Park, Jiwon S, Withers, Sita S, Modiano, Jaime F, Kent, Michael S, Chen, Mingyi, Luna, Jesus I, Culp, William TN, Sparger, Ellen E, Rebhun, Robert B, Monjazeb, Arta M, Murphy, William J, and Canter, Robert J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Genetics, Vaccine Related, Cancer, Biotechnology, Immunotherapy, Immunization, 5.1 Pharmaceuticals, Canine model, Cancer immunotherapy, Spontaneous cancer, Outbred, Murine model, Oncology and carcinogenesis
Abstract

Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populations of patients who will respond and who will experience at times significant toxicities. Although advances in cancer immunotherapy depend on preclinical testing, the majority of in-vivo testing currently relies on genetically identical inbred mouse models which, while offering critical insights regarding efficacy and mechanism of action, also vastly underrepresent the heterogeneity and complex interplay of human immune cells and cancers. Additionally, laboratory mice uncommonly develop spontaneous tumors, are housed under specific-pathogen free conditions which markedly impacts immune development, and incompletely model key aspects of the tumor/immune microenvironment. The canine model represents a powerful tool in cancer immunotherapy research as an important link between murine models and human clinical studies. Dogs represent an attractive outbred combination of companion animals that experience spontaneous cancer development in the setting of an intact immune system. This allows for study of complex immune interactions during the course of treatment while also directly addressing long-term efficacy and toxicity of cancer immunotherapies. However, immune dissection requires access to robust and validated immune assays and reagents as well as appropriate numbers for statistical evaluation. Canine studies will need further optimization of these important mechanistic tools for this model to fulfill its promise as a model for immunotherapy. This review aims to discuss the canine model in the context of existing preclinical cancer immunotherapy models to evaluate both its advantages and limitations, as well as highlighting its growth as a powerful tool in the burgeoning field of both human and veterinary immunotherapy.

Published
2016

20. Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

Author

Kim, Jong Hyuk, Schulte, Ashley J., Sarver, Aaron L., Lee, Donghee, Angelos, Mathew G., Frantz, Aric M., Forster, Colleen L., O'Brien, Timothy D., Cornax, Ingrid, O'Sullivan, M. Gerard, Cheng, Nuojin, Lewellen, Mitzi, Oseth, LeAnn, Kumar, Sunil, Bullman, Susan, Pedamallu, Chandra Sekhar, Goyal, Sagar M., Meyerson, Matthew, Lund, Troy C., Breen, Matthew, Lindblad-Toh, Kerstin, Dickerson, Erin B., Kaufman, Dan S., Modiano, Jaime F., Kim, Jong Hyuk, Schulte, Ashley J., Sarver, Aaron L., Lee, Donghee, Angelos, Mathew G., Frantz, Aric M., Forster, Colleen L., O'Brien, Timothy D., Cornax, Ingrid, O'Sullivan, M. Gerard, Cheng, Nuojin, Lewellen, Mitzi, Oseth, LeAnn, Kumar, Sunil, Bullman, Susan, Pedamallu, Chandra Sekhar, Goyal, Sagar M., Meyerson, Matthew, Lund, Troy C., Breen, Matthew, Lindblad-Toh, Kerstin, Dickerson, Erin B., Kaufman, Dan S., and Modiano, Jaime F.

Abstract

Hemangiosarcoma and angiosarcoma are soft-tissue sarcomas of blood vessel-forming cells in dogs and humans, respectively. These vasoformative sarcomas are aggressive and highly metastatic, with disorganized, irregular blood-filled vascular spaces. Our objective was to define molecular programs which support the niche that enables progression of canine hemangiosarcoma and human angiosarcoma. Dog-in-mouse hemangiosarcoma xenografts recapitulated the vasoformative and highly angiogenic morphology and molecular characteristics of primary tumors. Blood vessels in the tumors were complex and disorganized, and they were lined by both donor and host cells. In a series of xenografts, we observed that the transplanted hemangiosarcoma cells created exuberant myeloid hyperplasia and gave rise to lymphoproliferative tumors of mouse origin. Our functional analyses indicate that hemangiosarcoma cells generate a microenvironment that supports expansion and differentiation of hematopoietic progenitor populations. Furthermore, gene expression profiling data revealed hemangiosarcoma cells expressed a repertoire of hematopoietic cytokines capable of regulating the surrounding stromal cells. We conclude that canine hemangiosarcomas, and possibly human angiosarcomas, maintain molecular properties that provide hematopoietic support and facilitate stromal reactions, suggesting their potential involvement in promoting the growth of hematopoietic tumors.Significance: We demonstrate that hemangiosarcomas regulate molecular programs supporting hematopoietic expansion and differentiation, providing insights into their potential roles in creating a permissive stromal-immune environment for tumor progression.

Published
2024
Full Text
View/download PDF

21. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer

Author

Trott, Josephine F, Kim, Jeffrey, Abu Aboud, Omran, Wettersten, Hiromi, Stewart, Benjamin, Berryhill, Grace, Uzal, Francisco, Hovey, Russell C, Chen, Ching-Hsien, Anderson, Katie, Graef, Ashley, Sarver, Aaron L, Modiano, Jaime F, and Weiss, Robert H

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Kidney Disease, Cancer, Biotechnology, Rare Diseases, Animals, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Cell Line, Tumor, Humans, Indoleamine-Pyrrole 2, 3, -Dioxygenase, Indoles, Interferon-alpha, Kidney Neoplasms, Mice, Mice, Inbred BALB C, Thiohydantoins, Tryptophan, tryptophan, kynurenine, renal cell carcinoma, interferon-alpha, indolamine-2, 3-dioxygenase, 3-dioxygenase, indolamine-2, Oncology and carcinogenesis
Abstract

Renal cell carcinoma (RCC) is increasing in incidence, and a complete cure remains elusive. While immune-checkpoint antibodies are promising, interferon-based immunotherapy has been disappointing. Tryptophan metabolism, which produces immunosuppressive metabolites, is enhanced in RCC. Here we show indolamine-2,3-dioxygenase-1 (IDO1) expression, a kynurenine pathway enzyme, is increased not only in tumor cells but also in the microenvironment of human RCC compared to normal kidney tissues. Neither kynurenine metabolites nor IDO inhibitors affected the survival or proliferation of human RCC or murine renal cell adenocarcinoma (RENCA) cells in vitro. However, interferon-gamma (IFNγ) induced high levels of IDO1 in both RCC and RENCA cells, concomitant with enhanced kynurenine levels in conditioned media. Induction of IDO1 by IFNα was weaker than by IFNγ. Neither the IDO1 inhibitor methyl-thiohydantoin-DL-tryptophan (MTH-trp) nor IFNα alone inhibited RENCA tumor growth, however the combination of MTH-trp and IFNα reduced tumor growth compared to IFNα. Thus, the failure of IFNα therapy for human RCC is likely due to its inability to overcome the immunosuppressive environment created by increased IDO1. Based on our data, and given that IDO inhibitors are already in clinical trials for other malignancies, IFNα therapy with an IDO inhibitor should be revisited for RCC.

Published
2016

25. Contributors

Author

Amsellem, Pierre M., primary, Argyle, David J., additional, Avery, Anne C., additional, Bacon, Nicholas J., additional, Bailey, Dennis B., additional, Bergman, Philip J., additional, Biller, Barbara, additional, Bonnett, Brenda N., additional, Boston, Sarah E., additional, Burton, Jenna H., additional, Christensen, Neil I., additional, Clifford, Craig A., additional, Culp, William T.N., additional, Dow, Steven, additional, Ehrhart, Nicole P., additional, Fan, Timothy M., additional, Farese, James P., additional, Flesner, Brian K., additional, Friedrichs, Kristen R., additional, Fulkerson, Christopher M., additional, Garrett, Laura D., additional, Giancristofaro, Nicole, additional, Gordon, Ira K., additional, Gustafson, Daniel L., additional, Guth, Amanda, additional, Hauck, Marlene L., additional, Henry, Carolyn J., additional, Kamstock, Debra A., additional, Kent, Michael S., additional, Khanna, Chand, additional, Kim, Jong Hyuk, additional, Knapp, Deborah W., additional, Lana, Susan E., additional, LaRue, Susan M., additional, Lascelles, B. Duncan X., additional, Lawrence, Jessica A., additional, LeBlanc, Amy K., additional, Liptak, Julius M., additional, London, Cheryl A., additional, Lunn, Katharine F., additional, Macy, Dennis W., additional, Magee, Kara, additional, de Mello Souza, Carlos H., additional, Meneses, Constanza, additional, Miller, Paul E., additional, Modiano, Jaime F., additional, Moore, Peter F., additional, Mullin, Christine, additional, Mutsaers, Anthony J., additional, Nolan, Michael W., additional, Nykamp, Stephanie, additional, Oblak, Michelle L., additional, Page, Rodney L., additional, Pancotto, Theresa E., additional, Paoloni, Melissa C., additional, Pinkerton, Marie, additional, Powers, Barbara E., additional, Randall, Elissa, additional, Reagan, Jennifer K., additional, Rebhun, Robert B., additional, Robinson, Narda G., additional, Rossmeisl, John H., additional, Ruple, Audrey, additional, Russell, Duncan S., additional, Saba, Corey F., additional, Selmic, Laura E., additional, Selting, Kim A., additional, Shaw, Jane R., additional, Skinner, Owen T., additional, Skorupski, Katherine A., additional, Sorenmo, Karin U., additional, Stern, Joshua A., additional, Teixeira, Leandro B.C., additional, Thamm, Douglas H., additional, Turek, Michelle M., additional, Vail, David M., additional, Wakshlag, Joseph, additional, Withrow, Stephen J., additional, Woods, J. Paul, additional, Worley, Deanna R., additional, Young, Karen M., additional, and Zappulli, Valentina, additional

Published
2020
Full Text
View/download PDF

26. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance

Author

Lin, Pei-Yin, Fosmire, Susan P, Park, See-Hyoung, Park, Jin-Young, Baksh, Shairaz, Modiano, Jaime F, and Weiss, Robert H

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Genetics, Cancer, Kidney Disease, Aetiology, 2.1 Biological and endogenous factors, Animals, Apoptosis, Base Sequence, Cisplatin, Cyclin-Dependent Kinase Inhibitor p21, Cytosol, DNA Damage, Dogs, Down-Regulation, Enzyme Activation, Humans, Kidney Neoplasms, Molecular Sequence Data, PTEN Phosphohydrolase, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors, Proteasome Endopeptidase Complex, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, RNA Interference, Sirolimus, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

BackgroundThe PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) tumor suppressor gene is frequently mutated or deleted in a wide variety of solid tumors, and these cancers are generally more aggressive and difficult to treat than those possessing wild type PTEN. While PTEN lies upstream of the phosphoinositide-3 kinase signaling pathway, the mechanisms that mediate its effects on tumor survival remain incompletely understood. Renal cell carcinoma (RCC) is associated with frequent treatment failures (approximately 90% in metastatic cases), and these tumors frequently contain PTEN abnormalities.ResultsUsing the ACHN cell line containing wild type PTEN, we generated a stable PTEN knockdown RCC cell line using RNA interference. We then used this PTEN knockdown cell line to show that PTEN attenuation increases resistance to cisplatin-induced apoptosis, a finding associated with increased levels of the cyclin kinase inhibitor p21. Elevated levels of p21 result from stabilization of the protein, and they are dependent on the activities of phosphoinositide-3 kinase and Akt. More specifically, the accumulation of p21 occurs preferentially in the cytosolic compartment, which likely contributes to both cell cycle progression and resistance to apoptosis.ConclusionSince p21 regulates a decision point between repair and apoptosis after DNA damage, our data suggest that p21 plays a key role in mechanisms used by PTEN-deficient tumors to escape chemotherapy. This in turn raises the possibility to use p21 attenuators as chemotherapy sensitizers, an area under active continuing investigation in our laboratories.

Published
2007

28. Oncolytic vesicular stomatitis virus is safe and provides a survival benefit for dogs with naturally occurring osteosarcoma

Author

Makielski, Kelly M, primary, Sarver, Aaron L, additional, Henson, Michael S, additional, Stuebner, Kathleen M, additional, Borgatti, Antonella, additional, Suksanpaisan, Lukkan, additional, Preusser, Caitlin, additional, Tabaran, Alexandru-Flaviu, additional, Cornax, Ingrid, additional, O'Sullivan, M. Gerard, additional, Chehadeh, Andrea, additional, Groschen, Donna, additional, Bergsrud, Kelly, additional, Pracht, Sara, additional, Winter, Amber, additional, Mills, Lauren J, additional, Schwabenlander, Marc D, additional, Wolfe, Melissa, additional, Farrar, Michael A, additional, Cutter, Gary R, additional, Koopmeiners, Joseph S, additional, Russell, Stephen J, additional, Modiano, Jaime F, additional, and Naik, Shruthi, additional

Published
2023
Full Text
View/download PDF

30. Data from Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions

Author

Kim, Jong Hyuk, primary, Megquier, Kate, primary, Thomas, Rachael, primary, Sarver, Aaron L., primary, Song, Jung Min, primary, Kim, Yoon Tae, primary, Cheng, Nuojin, primary, Schulte, Ashley J., primary, Linden, Michael A., primary, Murugan, Paari, primary, Oseth, LeAnn, primary, Forster, Colleen L., primary, Elvers, Ingegerd, primary, Swofford, Ross, primary, Turner-Maier, Jason, primary, Karlsson, Elinor K., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, and Modiano, Jaime F., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Materials from Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR

Author

Borgatti, Antonella, primary, Koopmeiners, Joseph S., primary, Sarver, Aaron L., primary, Winter, Amber L., primary, Stuebner, Kathleen, primary, Todhunter, Deborah, primary, Rizzardi, Anthony E., primary, Henriksen, Jonathan C., primary, Schmechel, Stephen, primary, Forster, Colleen L., primary, Kim, Jong-Hyuk, primary, Froelich, Jerry, primary, Walz, Jillian, primary, Henson, Michael S., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Oh, Felix, primary, Pilbeam, Kristy, primary, Modiano, Jaime F., primary, and Vallera, Daniel A., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure S3 from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20

Author

Weiskopf, Kipp, primary, Anderson, Katie L., primary, Ito, Daisuke, primary, Schnorr, Peter J., primary, Tomiyasu, Hirotaka, primary, Ring, Aaron M., primary, Bloink, Kristin, primary, Efe, Jem, primary, Rue, Sarah, primary, Lowery, David, primary, Barkal, Amira, primary, Prohaska, Susan, primary, McKenna, Kelly M., primary, Cornax, Ingrid, primary, O'Brien, Timothy D., primary, O'Sullivan, M. Gerard, primary, Weissman, Irving L., primary, and Modiano, Jaime F., primary

Published
2023
Full Text
View/download PDF

34. Data from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20

Author

Weiskopf, Kipp, primary, Anderson, Katie L., primary, Ito, Daisuke, primary, Schnorr, Peter J., primary, Tomiyasu, Hirotaka, primary, Ring, Aaron M., primary, Bloink, Kristin, primary, Efe, Jem, primary, Rue, Sarah, primary, Lowery, David, primary, Barkal, Amira, primary, Prohaska, Susan, primary, McKenna, Kelly M., primary, Cornax, Ingrid, primary, O'Brien, Timothy D., primary, O'Sullivan, M. Gerard, primary, Weissman, Irving L., primary, and Modiano, Jaime F., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Tables 1-15 from Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions

Author

Kim, Jong Hyuk, primary, Megquier, Kate, primary, Thomas, Rachael, primary, Sarver, Aaron L., primary, Song, Jung Min, primary, Kim, Yoon Tae, primary, Cheng, Nuojin, primary, Schulte, Ashley J., primary, Linden, Michael A., primary, Murugan, Paari, primary, Oseth, LeAnn, primary, Forster, Colleen L., primary, Elvers, Ingegerd, primary, Swofford, Ross, primary, Turner-Maier, Jason, primary, Karlsson, Elinor K., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, and Modiano, Jaime F., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figures 1-12 from Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions

Author

Kim, Jong Hyuk, primary, Megquier, Kate, primary, Thomas, Rachael, primary, Sarver, Aaron L., primary, Song, Jung Min, primary, Kim, Yoon Tae, primary, Cheng, Nuojin, primary, Schulte, Ashley J., primary, Linden, Michael A., primary, Murugan, Paari, primary, Oseth, LeAnn, primary, Forster, Colleen L., primary, Elvers, Ingegerd, primary, Swofford, Ross, primary, Turner-Maier, Jason, primary, Karlsson, Elinor K., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, and Modiano, Jaime F., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Tables 1 through 3, Supplementary Figure Legends, and Supplementary Materials and Methods from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20

Author

Weiskopf, Kipp, primary, Anderson, Katie L., primary, Ito, Daisuke, primary, Schnorr, Peter J., primary, Tomiyasu, Hirotaka, primary, Ring, Aaron M., primary, Bloink, Kristin, primary, Efe, Jem, primary, Rue, Sarah, primary, Lowery, David, primary, Barkal, Amira, primary, Prohaska, Susan, primary, McKenna, Kelly M., primary, Cornax, Ingrid, primary, O'Brien, Timothy D., primary, O'Sullivan, M. Gerard, primary, Weissman, Irving L., primary, and Modiano, Jaime F., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Methods from Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma

Author

Megquier, Kate, primary, Turner-Maier, Jason, primary, Swofford, Ross, primary, Kim, Jong-Hyuk, primary, Sarver, Aaron L., primary, Wang, Chao, primary, Sakthikumar, Sharadha, primary, Johnson, Jeremy, primary, Koltookian, Michele, primary, Lewellen, Mitzi, primary, Scott, Milcah C., primary, Schulte, Ashley J., primary, Borst, Luke, primary, Tonomura, Noriko, primary, Alfoldi, Jessica, primary, Painter, Corrie, primary, Thomas, Rachael, primary, Karlsson, Elinor K., primary, Breen, Matthew, primary, Modiano, Jaime F., primary, Elvers, Ingegerd, primary, and Lindblad-Toh, Kerstin, primary

Published
2023
Full Text
View/download PDF

39. Data from Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma

Author

Megquier, Kate, primary, Turner-Maier, Jason, primary, Swofford, Ross, primary, Kim, Jong-Hyuk, primary, Sarver, Aaron L., primary, Wang, Chao, primary, Sakthikumar, Sharadha, primary, Johnson, Jeremy, primary, Koltookian, Michele, primary, Lewellen, Mitzi, primary, Scott, Milcah C., primary, Schulte, Ashley J., primary, Borst, Luke, primary, Tonomura, Noriko, primary, Alfoldi, Jessica, primary, Painter, Corrie, primary, Thomas, Rachael, primary, Karlsson, Elinor K., primary, Breen, Matthew, primary, Modiano, Jaime F., primary, Elvers, Ingegerd, primary, and Lindblad-Toh, Kerstin, primary

Published
2023
Full Text
View/download PDF

40. Data from Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR

Author

Borgatti, Antonella, primary, Koopmeiners, Joseph S., primary, Sarver, Aaron L., primary, Winter, Amber L., primary, Stuebner, Kathleen, primary, Todhunter, Deborah, primary, Rizzardi, Anthony E., primary, Henriksen, Jonathan C., primary, Schmechel, Stephen, primary, Forster, Colleen L., primary, Kim, Jong-Hyuk, primary, Froelich, Jerry, primary, Walz, Jillian, primary, Henson, Michael S., primary, Breen, Matthew, primary, Lindblad-Toh, Kerstin, primary, Oh, Felix, primary, Pilbeam, Kristy, primary, Modiano, Jaime F., primary, and Vallera, Daniel A., primary

Published
2023
Full Text
View/download PDF

41. Supplemental Table 7 from Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma

Author

Megquier, Kate, primary, Turner-Maier, Jason, primary, Swofford, Ross, primary, Kim, Jong-Hyuk, primary, Sarver, Aaron L., primary, Wang, Chao, primary, Sakthikumar, Sharadha, primary, Johnson, Jeremy, primary, Koltookian, Michele, primary, Lewellen, Mitzi, primary, Scott, Milcah C., primary, Schulte, Ashley J., primary, Borst, Luke, primary, Tonomura, Noriko, primary, Alfoldi, Jessica, primary, Painter, Corrie, primary, Thomas, Rachael, primary, Karlsson, Elinor K., primary, Breen, Matthew, primary, Modiano, Jaime F., primary, Elvers, Ingegerd, primary, and Lindblad-Toh, Kerstin, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Tables and Figures from Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma

Author

Megquier, Kate, primary, Turner-Maier, Jason, primary, Swofford, Ross, primary, Kim, Jong-Hyuk, primary, Sarver, Aaron L., primary, Wang, Chao, primary, Sakthikumar, Sharadha, primary, Johnson, Jeremy, primary, Koltookian, Michele, primary, Lewellen, Mitzi, primary, Scott, Milcah C., primary, Schulte, Ashley J., primary, Borst, Luke, primary, Tonomura, Noriko, primary, Alfoldi, Jessica, primary, Painter, Corrie, primary, Thomas, Rachael, primary, Karlsson, Elinor K., primary, Breen, Matthew, primary, Modiano, Jaime F., primary, Elvers, Ingegerd, primary, and Lindblad-Toh, Kerstin, primary

Published
2023
Full Text
View/download PDF

43. Supplemental Table 3 from Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma

Author

Scott, Milcah C., primary, Temiz, Nuri A., primary, Sarver, Anne E., primary, LaRue, Rebecca S., primary, Rathe, Susan K., primary, Varshney, Jyotika, primary, Wolf, Natalie K., primary, Moriarity, Branden S., primary, O'Brien, Timothy D., primary, Spector, Logan G., primary, Largaespada, David A., primary, Modiano, Jaime F., primary, Subramanian, Subbaya, primary, and Sarver, Aaron L., primary

Published
2023
Full Text
View/download PDF

44. Supplemental Table 6 from Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma

Author

Scott, Milcah C., primary, Temiz, Nuri A., primary, Sarver, Anne E., primary, LaRue, Rebecca S., primary, Rathe, Susan K., primary, Varshney, Jyotika, primary, Wolf, Natalie K., primary, Moriarity, Branden S., primary, O'Brien, Timothy D., primary, Spector, Logan G., primary, Largaespada, David A., primary, Modiano, Jaime F., primary, Subramanian, Subbaya, primary, and Sarver, Aaron L., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Data and Figures from Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma

Author

Scott, Milcah C., primary, Temiz, Nuri A., primary, Sarver, Anne E., primary, LaRue, Rebecca S., primary, Rathe, Susan K., primary, Varshney, Jyotika, primary, Wolf, Natalie K., primary, Moriarity, Branden S., primary, O'Brien, Timothy D., primary, Spector, Logan G., primary, Largaespada, David A., primary, Modiano, Jaime F., primary, Subramanian, Subbaya, primary, and Sarver, Aaron L., primary

Published
2023
Full Text
View/download PDF

46. Data from Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma

Author

Scott, Milcah C., primary, Temiz, Nuri A., primary, Sarver, Anne E., primary, LaRue, Rebecca S., primary, Rathe, Susan K., primary, Varshney, Jyotika, primary, Wolf, Natalie K., primary, Moriarity, Branden S., primary, O'Brien, Timothy D., primary, Spector, Logan G., primary, Largaespada, David A., primary, Modiano, Jaime F., primary, Subramanian, Subbaya, primary, and Sarver, Aaron L., primary

Published
2023
Full Text
View/download PDF

47. Supplemental Table 2 from Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma

Author

Scott, Milcah C., primary, Temiz, Nuri A., primary, Sarver, Anne E., primary, LaRue, Rebecca S., primary, Rathe, Susan K., primary, Varshney, Jyotika, primary, Wolf, Natalie K., primary, Moriarity, Branden S., primary, O'Brien, Timothy D., primary, Spector, Logan G., primary, Largaespada, David A., primary, Modiano, Jaime F., primary, Subramanian, Subbaya, primary, and Sarver, Aaron L., primary

Published
2023
Full Text
View/download PDF

48. Supplemental Table 5 from Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma

Author

Scott, Milcah C., primary, Temiz, Nuri A., primary, Sarver, Anne E., primary, LaRue, Rebecca S., primary, Rathe, Susan K., primary, Varshney, Jyotika, primary, Wolf, Natalie K., primary, Moriarity, Branden S., primary, O'Brien, Timothy D., primary, Spector, Logan G., primary, Largaespada, David A., primary, Modiano, Jaime F., primary, Subramanian, Subbaya, primary, and Sarver, Aaron L., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figures 1-8 from SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma

Author

Sakthikumar, Sharadha, primary, Elvers, Ingegerd, primary, Kim, Jaegil, primary, Arendt, Maja L., primary, Thomas, Rachael, primary, Turner-Maier, Jason, primary, Swofford, Ross, primary, Johnson, Jeremy, primary, Schumacher, Steven E., primary, Alföldi, Jessica, primary, Axelsson, Erik, primary, Couto, C. Guillermo, primary, Kisseberth, William C., primary, Pettersson, Mats E., primary, Getz, Gad, primary, Meadows, Jennifer R.S., primary, Modiano, Jaime F., primary, Breen, Matthew, primary, Kierczak, Marcin, primary, Forsberg-Nilsson, Karin, primary, Marinescu, Voichita D., primary, and Lindblad-Toh, Kerstin, primary

Published
2023
Full Text
View/download PDF

50. Supplemental Table 1 from Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma

Author

Scott, Milcah C., primary, Temiz, Nuri A., primary, Sarver, Anne E., primary, LaRue, Rebecca S., primary, Rathe, Susan K., primary, Varshney, Jyotika, primary, Wolf, Natalie K., primary, Moriarity, Branden S., primary, O'Brien, Timothy D., primary, Spector, Logan G., primary, Largaespada, David A., primary, Modiano, Jaime F., primary, Subramanian, Subbaya, primary, and Sarver, Aaron L., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results